Amneal Pharmaceuticals (AMRX Quick QuoteAMRX - Free Report) reported $814.32 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 11.5%. EPS of $0.21 for the same period compares to $0.12 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $815.87 million, representing a surprise of -0.19%. The company delivered an EPS surprise of +18.85%, with the consensus EPS estimate being $0.18.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Amneal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenue- Affordable Medicines Segment: $436.65 million compared to the $478.58 million average estimate based on three analysts. The reported number represents a change of -0.6% year over year.
• Net Revenue- AvKARE Segment: $210.74 million compared to the $214.01 million average estimate based on three analysts. The reported number represents a change of +23.7% year over year.
• Net Revenue- Specialty Segment: $166.93 million versus $123.28 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +38.1% change.

View all Key Company Metrics for Amneal here>>>

Shares of Amneal have returned +2.7% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.